ADCT Short Volume

ADC Therapeutics S.A. (ADCT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $442.6M, listed on NYSE, employing roughly 263 people, carrying a beta of 1.84 to the broader market. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Led by Ameet Mallik, public since 2020-05-18.

Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.

Latest Date
2026-05-15
Short Volume
220.5K
Total Volume
389.2K
Short %
56.67%
30-Day Avg Short %
44.71%

Showing 30 days of FINRA short volume data for ADC Therapeutics S.A..

Learn how short volume is reported and how to read the data →

Frequently asked ADCT short volume questions

What is the daily ADCT short volume?
As of May 15, 2026, ADC Therapeutics S.A. (ADCT) short volume is 220.5K shares against 389.2K total reported volume, or 56.67% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
How is ADCT short volume reported?
FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
What does ADCT short volume tell options traders?
Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.